Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 4/20 | 0.83 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.83 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961678 | 0.91 | CPT1A (1.00) | CPT1ACPT1BP2RY14KDM4C | |
| SCHEMBL960972 | 0.90 | CPT1A (0.88) | CPT1ACPT1BP2RY14KDM4CCPT2 | |
| SCHEMBL961693 | 0.89 | CPT1A (0.83) | CPT1ACPT1BP2RY14TP53KDM4C | |
| SCHEMBL963612 | 0.88 | CPT1A (0.65) | CPT1ACPT1BRAB9AGAAMEN1 | |
| SCHEMBL962451 | 0.87 | CPT1A (0.80) | CPT1ACPT1BRAB9AMAPTTP53 | |
| SCHEMBL958061 | 0.87 | CPT1A (0.74) | CPT1ACPT1BRAB9AMAPTTP53 | |
| SCHEMBL960160 | 0.84 | CPT1A (0.75) | CPT1ACPT1BKDM4CSMN1; SMN2MEN1 | |
| SCHEMBL958863 | 0.84 | CPT1A (0.72) | CPT1ACPT1BSMN1; SMN2 | |
| SCHEMBL963276 | 0.83 | CPT1A (0.58) | CPT1ACPT1BP2RY14RAB9AGAA | |
| SCHEMBL961367 | 0.82 | CPT1A (0.57) | CPT1ACPT1BRAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885P2RY14 1643/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885P2RY14 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.